Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections

BACKGROUND: Immune checkpoint inhibitors (ICI) substantially improve outcome for patients with cancer. However, the majority of patients develops immune-related adverse events (irAEs), which can be persistent and significantly reduce quality of life. Neurological irAEs occur in 1–5% of patients and...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmitt, C., Hoefsmit, E. P., Fangmeier, T., Kramer, N., Kabakci, C., Vera González, J., Versluis, J. M., Compter, A., Harrer, T., Mijočević, H., Schubert, S., Hundsberger, T., Menzies, A. M., Scolyer, R. A., Long, G. V., French, L. E., Blank, C. U., Heinzerling, L. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576679/
https://www.ncbi.nlm.nih.gov/pubmed/37606856
http://dx.doi.org/10.1007/s00262-023-03498-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576679/
https://www.ncbi.nlm.nih.gov/pubmed/37606856
http://dx.doi.org/10.1007/s00262-023-03498-0

Ejemplares similares